<ul>
<li>Dyne Therapeutics director Jason P. Rhodes disclosed sales of common stock on April 23-27.     *      Transactions totaled 384,549 shares at weighted average prices of $19.19, $18.48, $18.15.     *      Post-transaction holdings included 5.22 million shares indirectly held through Atlas Venture Fund XI.     *      Indirect holdings also included 1.64 million shares through Atlas Venture Opportunity Fund II.     *      Filing reported 1.21 million shares indirectly held through Atlas Venture Opportunity Fund I. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001577014-26-000004), on April 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

SBIO

LABU

<p>Dyne Therapeutics director Jason P. Rhodes sold 384,549 shares of common stock between April 23-27, totaling $6.76 million at average prices of $19.19, $18.48, and $18.15. After these transactions, he holds 5.22 million shares indirectly through Atlas Venture Fund XI, 1.64 million shares through Atlas Venture Opportunity Fund II, and 1.21 million shares through Atlas Venture Opportunity Fund I.</p>

PUBT

Dyne Therapeutics

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Dyne Therapeutics Director Jason P. Rhodes disposes of $6.76 million in shares